The gastrointestinal (GI) tract is the system of organs by which food is ingested and digested, nutrients are absorbed, and waste products are eliminated. GI cell proliferation is essential for maintaining normal physiological function and integrity of the protective epithelial barrier, however, as many GI cells turn over at a rapid rate, normal function and barrier maintenance are highly sensitive to toxic insults. When drug-induced GI toxicity occurs, either by cytotoxicity, inhibition of cell proliferation, or adverse pharmacological effect on receptors and enzymes, damage manifests with a variety of clinical symptoms including nausea, vomiting, ulceration, and diarrhea. It is essential to understand and minimize these consequences, thus AstraZeneca seeks a translationally relevant in vitro model to investigate gastrointestinal toxicity onset and recovery.
This is a Reduction-to-Practice Challenge that requires written documentation, experimental proof-of-concept data, and validation results.
Source: InnoCentive Challenge ID: 9933828
Obstructive Sleep Apnea (OSA) affects millions of individuals in the United States and many more worldwide. Fortunately, an effective non-surgical treatment exists in the form of a continuous positive airway pressure (CPAP) device used while sleeping. Unfortunately, adherence to the use of a CPAP for people diagnosed with OSA lies in the 40-50% range despite past efforts to improve devices and educate patients. The Seeker is looking for innovative solutions for increasing adherence to CPAP treatment for OSA. Solutions may take a wide range of approaches to address the psychological, physical, or comfort issues faced by people who should be using a CPAP but are not.
This is an Ideation Challenge with a guaranteed award for at least one submitted solution.
Source: InnoCentive Challenge ID: 9933907
The next generation of mobile data connectivity is just around the corner with 5G technology expected to be in use by 2020. 5G connectivity is expected to greatly enhance performance compared to existing 4G systems with improvements of at least a factor of 10 for data rates, latency, and number of simultaneous connections as well enhanced mobility. The Seeker is looking for new ideas for features, products, and services enabled by the availability of this disruptive 5G technology.
Source: InnoCentive Challenge ID: 9933910
Nearly 3 million people in the United States and 65 million people worldwide have epilepsy, a neurological condition which affects the nervous system and causes seizures. One in 26 people will develop epilepsy at some point in their lifetime, with 150,000 new cases annually in the United States. Nearly 80% of the people with epilepsy live in low- and middle-income countries and three-quarters of these individuals do not get the treatment they need.
Among those living with epilepsy, nearly one-third have ongoing seizures despite existing therapies. Each year, more than 1 out of 1,000 people with epilepsy die from sudden unexpected death in epilepsy (SUDEP). If seizures are uncontrolled, the risk of SUDEP increases to more than 1 out of 150. SUDEP is the leading cause of death in young adults with uncontrolled seizures.
In order to accelerate the identification of effective treatments for SUDEP, the Epilepsy Foundation SUDEP Institute is sponsoring a Reduction to Practice Challenge to develop a predictive biomarker or panel of biomarkers to identify people at risk for SUDEP or seizures that compromise cardiac or respiratory function. The biomarker(s) must serve as an endpoint or surrogate endpoint that will drive human SUDEP interventions. For example, the biomarker(s) may identify a high risk patient group that could be used to test existing candidate interventions such as seizure detection devices.
Milestone 1 requires a detailed Project Plan of the proposed solution. Milestone 2 involves the production of proof-of-concept data. Milestone 3 requires results that demonstrate the predictive efficacy of the biomarker(s). The SUDEP Institute intends to make up to 10 awards from a total award pool of $100,000 for Milestone 1, up to 4 awards of $25,000 each for Milestone 2, and a final award at least $800,000 for successful completion of Milestone 3.
Solvers are encouraged to enter this Challenge even if they were not involved in The SUDEP Institute Challenge: Predictive Biomarkers of Epilepsy – Challenge 9933719. Participants from the previous Challenge may elect to expound upon their (winning) solution or pursue another idea. Solvers should note that the Center for SUDEP Research (CSR) is an NIH-funded research collaborative studying animal models of SUDEP and epilepsy patients who may be at high risk for SUDEP. Solvers may contact the CSR at email@example.com to request data and/or biospecimens to be used in the execution of a Solution. Other resources that Solvers may access are through the North American SUDEP Registry and the Center for Disease Control and Prevention (CDC) Sudden Death in the Young Registry.
This is a Reduction to Practice Challenge that requires written documentation, experimental proof-of-concept data, and biomarker validation data.
Source: InnoCentive Challenge ID: 9933784
Recycled paper fibers from books, magazines, etc., are used to produce carton board. These waste fibers carry with them residues of hydrophobic adhesives – “stickies” – that tend to form lumps that cause disruptions in the board production line and defective goods, both with high economic consequences.
The Seeker is looking for new methods to prevent the formation of such lumps, either by removing the residual stickies or neutralizing their adhesive properties that cause the lumps.
This is a Reduction-to-Practice Challenge that requires submission of written documentation from the Solver. The Seeker will perform experimental validation of proposed solutions in order to determine the award.
Source: InnoCentive Challenge ID: 9933878
Bringing a new pharmaceutical to market is a long, expensive, and complex process that encompasses research, development, approval, and commercialization. Many promising drug candidates fail in the clinic due to shortcomings in their efficacy, safety, or tolerability. Advances have been made to mitigate these issues and these include the identification of translational biomarkers, improvements in finding and optimization of small molecules or antibodies as established therapeutic modalities, and the use of more predictive models reflecting novel disease concepts. These strategies are effective, yet they might not lead to the next breakthrough therapy. Therefore, Boehringer Ingelheim (the Seeker) is looking one step further to find novel therapeutic modalities that have the potential to modulate targets of human disease including such that are usually not amenable by established modalities. Thus, Boehringer Ingelheim (the Seeker) desires partners to find and develop emerging modalities that have high potential to treat or modulate human disease.
This is an electronic Request-for-Partners (eRFP) Challenge; the Solver will only need to submit a written proposal to be evaluated by Boehringer Ingelheim with the goal of establishing a collaborative partnership.
Source: InnoCentive Challenge ID: 9933874
Currently, it is possible to process high starch to protein ratio food like corn, rice and wheat to expand and “puff-up” the material to make a crunchy texture in a shape similar to the original. These processes do not work on low starch to protein ratio, more dense, high fiber and oily food materials like seeds and nuts. The Seeker would like to find processes that could accomplish this expansion on such more nutritious foods that are relatively higher in protein, fiber and fat than commonly expandable starchy grains and seeds.
This Theoretical Challenge requires only a written proposal.
Source: InnoCentive Challenge ID: 9933813
Aluminum sulfate Al2(SO4)3 is used as a coagulant in a water treatment process to obtain clarified water. The clarified water is further directed to demineralization (for feed boilers). While aluminum sulfate is effective in achieving the desired result, its use is associated with unacceptably high aluminum content in wastewater (> 0.04 mg/dm3 soluble aluminum). The Seeker for this Challenge is looking for an effective coagulant/process to cost-effectively treat the water without the negative side effect of high aluminum content in the effluent water.
Source: InnoCentive Challenge ID: 9933875
The Seeker is looking for an alternative humectant than those traditionally used in the food industry. They need materials and processes to be food safe. Ingredients would be preferably natural and considered “clean label”.
Source: InnoCentive Challenge ID: 9933814
Current methods to recover sulfates from wastewater streams are limited in their capability to work in challenging industrial conditions and/or to generate a new revenue stream from the recovered sulfates. Hence, SUEZ is looking for a solution to solve these two limitations.
Source: InnoCentive Challenge ID: 9933861